Insulet price target raised to $355 from $310 at Citi

Citi raised the firm’s price target on Insulet (PODD) to $355 from $310 and keeps a Buy rating on the shares. The company’s Q4 delivery was better than expected and the 2025 guidance is better than Citi modeled, the analyst tells investors in a research note. The firm says Insulet has posted nine consecutive years of 20%-plus growth.